Table 1.
Baseline patient characteristics. (For continuous variables, means and standard deviations are reported, absolute numbers and percentages for proportions).
| Characteristic | Number |
|---|---|
| Age (years) | 58.5 (10.1) |
| Gender | |
| Male | 112 (84.2%) |
| Female | 21 (15.8%) |
| Baseline weight (kg) | 86.0 (18.3) |
| Disease | |
| SCC | 123 (92.5%) |
| T0-2 | 77 (62.6%) |
| T3-4 | 46 (37.4%) |
| N0-1 | 45 (36.6%) |
| N2a-3 | 78 (63.4%) |
| Oropharynx | 84 (68.3%) |
| Oral cavity | 12 (9.8%) |
| Larynx | 11 (8.9%) |
| Hypopharynx | 5 (4.1%) |
| Nasopharynx | 3 (2.4%) |
| Unknown primary/Other | 8 (6.5%) |
| Salivary gland | 10 (7.5%) |
| Dose/fractionation | |
| 70/35 | 3 (2.3%) |
| 68/34* | 13 (9.8%) |
| 65/30* | 88 (66.1%) |
| 60/30 | 29 (21.8%) |
| Neck irradiation | |
| Unilateral | 38 (28.6%) |
| Bilateral | 95 (71.4%) |
| Systemic therapy | |
| Cisplatin† | 75 (56.4%) |
| Cetuximab† | 11 (8.3%) |
| None | 47 (35.3%) |
*
Primary SCCs of the oro/hypopharynx, and larynx treated with 68 Gy/34# prior to November 2011, 65 Gy/30# thereafter.
†
Dose: cisplatin – 40 mg/m2 weekly, cetuximab 400 mg/m2 loading dose, 240 mg/m2 weekly thereafter.